Suppr超能文献

缺铁性贫血对非糖尿病患者糖化血红蛋白水平的影响。

Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients.

作者信息

Coban Erkan, Ozdogan Mustafa, Timuragaoglu Aysen

机构信息

Department of Internal Medicine, Akdeniz University, Faculty of Medicine, Antalya, Turkey.

出版信息

Acta Haematol. 2004;112(3):126-8. doi: 10.1159/000079722.

Abstract

The major form of glycohemoglobin is hemoglobin A1c (HbA1c). The HbA1c fraction is abnormally elevated in chronic hyperglycemic diabetic patients and correlates positively with glycemic control. Previous studies suggest that iron deficiency anemia (IDA) affects the levels of HbA1c. The aim of this study was to determine the effect of IDA on HbA1c levels in nondiabetic patients. The population studied consisted of 50 patients (30 women, 20 men, mean age 35.7 +/- 11.9 years) with IDA and 50 healthy subjects that were matched for age and sex. Patients who had glucose tolerance abnormalities (impaired glucose tolerance or diabetes mellitus), hemoglobinopathies, hemolytic anemia, chronic alcohol ingestion and chronic renal failure were excluded from the study. Hematologic investigations, fasting and postprandial glucose and HbA1c levels were measured in all subjects before iron therapy. All patients with IDA were treated with iron 100 mg/day for 3 months. We repeated the laboratory investigation after iron therapy. Before iron treatment, the mean HbA1c (7.4 +/- 0.8%) level in patients with IDA was higher than in a healthy group (5.9% +/- 0.5) (p < 0.001). In patients with IDA, HbA1c decreased significantly after iron treatment from a mean of 7.4% +/- 0.8 to 6.2% +/- 0.6 (p < 0.001). Iron deficiency must be corrected before any diagnostic or therapeutic decision is made based on HbA1c.

摘要

糖化血红蛋白的主要形式是血红蛋白A1c(HbA1c)。在慢性高血糖糖尿病患者中,HbA1c比例异常升高,且与血糖控制呈正相关。先前的研究表明,缺铁性贫血(IDA)会影响HbA1c水平。本研究的目的是确定IDA对非糖尿病患者HbA1c水平的影响。研究人群包括50例IDA患者(30名女性,20名男性,平均年龄35.7±11.9岁)和50名年龄和性别相匹配的健康受试者。患有葡萄糖耐量异常(糖耐量受损或糖尿病)、血红蛋白病、溶血性贫血、长期饮酒和慢性肾衰竭的患者被排除在研究之外。在所有受试者接受铁剂治疗前,进行血液学检查、测量空腹及餐后血糖和HbA1c水平。所有IDA患者均接受每日100mg铁剂治疗,为期3个月。铁剂治疗后,我们重复进行了实验室检查。铁剂治疗前,IDA患者的平均HbA1c水平(7.4±0.8%)高于健康组(5.9%±0.5)(p<0.001)。在IDA患者中,铁剂治疗后HbA1c从平均7.4%±0.8显著降至6.2%±0.6(p<0.001)。在基于HbA1c做出任何诊断或治疗决定之前,必须纠正缺铁状态。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验